Sociedad Americana de Hirudoterapia

Efficacy and potential mechanism of atherosclerosis prevention by the active components of leech based on network pharmacology

Network pharmacology study published in Heliyon (2024)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportDesarrollo de fármacosFarmacología salivalLv Q et al. · Heliyon, 2024

Abstract

INTRODUCTION: Leeches are flesh-eating and bloodsucking parasitic worms. They are being used as a traditional Chinese medicine for centuries in activating blood and dissolving statis, dreging the meridims and tick. Hirudin, an active peptide product present in leech, has blood anticoagulant property and can assist in the treatment of thrombosis and diseases related to blood circulation. The efficacy and potential mechanism of action of leeches in such diseases should be further explored. MATERIALS AND METHODS: First, network pharmacology was used to screen the predicted potential targets of the active constituents of leech and AS. The common targets of the active constituents of leech and AS were obtained using Venn diagram. Further, the drug-active-constituent-target network diagram, protein-protein interaction, and GO and KEGG pathway enrichment analyses were used to construct the active-constituent-AS target-pathway network diagram. Subsequently, the protein-drug molecule docking model was drawn. Finally, the results of network pharmacology were validated using a mouse model of AS. RESULTS: In total, 34 active constituents of leech and 1172 AS-related gene targets were selected, took the drug action targets and potential disease targets to get the common targets, and took the top 10 of degree value as the main active constituents for the treatment of atherosclerosis. There were 89 common targets and 12 core targets. The main targets included MAPK, EGFR, PIK3CB, etc. Potential regulatory pathways included cancer pathways, EGFR tyrosine kinase inhibitor resistance, Rap1 signaling pathway, PPAR signaling pathway, PI3K-Akt signaling pathway, C-type lectin receptor signaling pathway, and AGE-RAGE signaling pathway in diabetic complications. Animal experiments using mouse model of AS confirmed that AS plaques were smaller after treatment with leeches. SRC level was measured using western blotting. Expression of SRC in myocardial tissue was remarkably lower in the mice treated with leech than in the mice from model group fed on high-fat chow. CONCLUSIONS: To the best of our knowledge, this is the first study to explore the mechanism of action of the active components of leech in AS prevention. The active components of leeches play a coordinated role in preventing AS through multicomponent, multitarget, and multichannel mechanism of action related to inflammatory response, oxidative stress, and lipid metabolism. This study provided a reference for subsequent cellular and animal experiments.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Network pharmacology combined with animal experiments showing leech extract's anti-atherosclerotic effects via PI3K/AKT, MAPK, and NF-κB pathway modulation.

Por qué esto importa para la hirudoterapia

Este estudio empleó farmacología de redes para predecir dianas y vías de los constituyentes activos de la sanguijuela en la aterosclerosis (AS), y posteriormente validó los hallazgos en un modelo murino de AS, observando reducción del tamaño de la placa y disminución de la expresión de SRC en el tejido miocárdico tras el tratamiento con sanguijuela. El trabajo es relevante para el dominio de ASH ya que examina componentes medicinales de la sanguijuela entera y su potencial antiaterosclerótico mediante mecanismos multidiana que involucran respuesta inflamatoria, estrés oxidativo y metabolismo lipídico. Sin embargo, el estudio es preclínico (solo modelo murino) y de enfoque computacional y animal; no aísla componentes específicos del secretoma ni aporta datos clínicos en humanos, y la preparación exacta de la sanguijuela utilizada no se detalla en el resumen. Por tanto, la relevancia es indirecta y preliminar.

Citación

Efficacy and potential mechanism of atherosclerosis prevention by the active components of leech based on network pharmacology.

Lv Q et al. · Heliyon, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.